Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM) Fair Value & Analysis
Healthcare · IN · Market cap ₹592M
Fair value as of: Jun 29, 2026
Analysis
Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM) currently trades at ₹36.07, while our model-based Fair Value estimate is ₹29.10 — implying the stock looks roughly 19.3% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Biofil Chemicals and Pharmaceuticals Limited engages in manufacturing and trading of pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and packaging solutions. It also provides job work service for manufacturing pharmaceutical drugs. Biofil Chemicals and Pharmaceuticals Limited was incorporated in 1985 and is based in Indore, India.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM) undervalued?
What is the fair value of BIOFILCHEM?
What is the quality score of BIOFILCHEM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.